<DOC>
	<DOCNO>NCT01373567</DOCNO>
	<brief_summary>Psoriasis chronic inflammatory hyperproliferative disease skin affect approximately 2 % world 's population.This phase IV study plan monitor performance Tinefcon patient suffer psoriasis condition actual use fulfill requirement monitor adverse drug reaction ( ADRs ) psoriasis patient treat Tinefcon . This study add literature risk benefit Tinefcon novel oral TNF-alpha release inhibitor .</brief_summary>
	<brief_title>A Phase IV Clinical Trial Study Safety , Tolerability Efficacy Tinefcon Patients With Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subjects least 18 year age clinical diagnosis plaque psoriasis Subject understand willing sign inform consent document start study specific assessment Pregnant lactating female Subject active infection , acute chronic due bacteria , virus , fungi parasite ( notably tuberculosis , chronic hepatitis B ) Subject heart failure ( New York Heart Association class III IV ) Subject demyelinate disease Subject solid cancer hematologic malignancy diagnose within last 5 year potential progression Women childbearing potential [ define sexually mature woman undergone hysterectomy naturally postmenopausal least 24 consecutive month ( i.e . menses time precede 24 consecutive month ) ] men , agree use adequate contraception ( e.g. , hormonal barrier method birth control abstinence ) signing informed consent document ( ICD ) , duration study participation least 4 week withdrawal study , unless surgically sterilize Subject situation associate high risk infection latent untreated tuberculosis , joint prosthesis infection within last 12 month , indwell urinary catheter , uncontrolled diabetes , chronic obstructive pulmonary disease , skin ulcer Subject know premalignant lesion ( polyps colon urinary bladder , cervical dysplasia myelodysplasia ) Subject know seropositive and/or clinically suspect human immunodeficiency virus infection Subject condition might make difficult subject participate study , discretion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Plaque Psoriasis</keyword>
</DOC>